LDS/Medical Tests/Ataxia Telangiectasia Mutated (ATM)

Ataxia Telangiectasia Mutated (ATM)

Ataxia-telangiectasia is a very rare condition characterized by progressive ataxia, cerebral atrophy, progressive neurological damage, and cutaneous telangiectasia. It manifests in an autosomal recessive pattern. Patients with the condition usually present with difficulty in walking and movement control. Simultaneously, there is dilation of blood vessels on the sclera and making the eyes appear red and bloodshot. Patients also have a higher incidence of malignancies, specifically relating to hematologic and breast. These dilated blood vessels however do not bleed. Other symptoms associated are early aging, grey tinge in cutaneous tissues, decreased innate immunity, and mild cognitive impairment. The known cause of ataxia telangiectasia is the abnormalities in the ATX gene.

The ATX gene is located on the long arm (q) of chromosome 11 at positions 22-23 and codes for the ATM protein. The protein is specifically localized in the nucleus and is associated with controlled development of the body and regulating the activity. The protein is found to play an important role in the nervous and immune systems. The protein acts as a DNA repair system and a cell cycle regulator. Human DNA is prone to damage from different factors including radiation and chemicals. These agents cause DNA damage, but luckily effective repair systems exist among which is the ATM protein. In the cell cycle, the protein phosphorylates target enzymes and proceeds for division. It prevents faulty cell division by inducing programmed cell death (apoptosis) in cells with irreversibly damaged DNA. The resultant uncontrolled division of cells with damaged DNA leads to the formation of various cancers. Hundreds of germline mutations in the ATX gene are now identified which cause deficient ATM protein or compromise its activity, causing ataxia-telangiectasia.

  • Confirms the diagnosis of ataxia-telangiectasia
  • Useful in the differential diagnosis of other recessive forms of ataxia
  • Aids in the distinction of pure ataxia-telangiectasia from ataxia telangiectasia-like disorders (ATLD)
  • Useful in screening neonates and family members at risk
A positive result indicates the presence of mutation or pathogenic variants in the ATX gene. A negative result indicates the absence of mutation or pathogenic variants in the ATX gene.

Negative for mutations analysis (no mutations or pathogenic variants detected)

Real-time Polymerase Chain Reaction (PCR), Multiplex Ligation-dependent Probe Amplification (MLPA), Next Generation Sequencing (NGS).

Whole blood, Lavender (K2EDTA), or Yellow-top (ACD) tube.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 6 months
Serum protein electrophoresis, immunoglobulin subclass, alpha-fetoprotein, Friedreich Ataxia Repeat Expansion, FXN (frataxin) Gene Analysis. Immunoglobulin IgG and IgA.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login